Metagenomi Therapeutics Inc (MGX) FinancialsMGXMetagenomi Therapeutics Inc

Evaluating the bottom line, Metagenomi Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5384.46%, while the net margin is -5100.00%. These profitability ratios, combined with a Return on Equity (ROE) of -60.61%, provide a clear picture of how effectively MGX converts its operational activities into shareholder value.

In the context of the broader market, MGX competes directly with industry leaders such as AARD and BLRX. With a market capitalization of $26.50M, it holds a leading position in the sector. When comparing efficiency, MGX's gross margin of 100.00% stands against AARD's N/A and BLRX's 53.40%. Such benchmarking helps identify whether Metagenomi Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Metagenomi has shown declining revenues and increasing losses, with a net income of -27.48 million USD for Q2 2026 and a gross margin consistently at 100%.